急性加重史对中重度未控制哮喘患者度普利尤单抗临床反应的影响
LIBERTY ASTHMA QUEST 研究的事后分析评估度普利尤单抗在2型高表达哮喘患者中的疗效是否受既往急性加重次数影响。结果显示,无论既往急性加重史和基线ICS剂量如何,度普利尤单抗均显著减少重度急性加重、改善FEV1和哮喘控制,且既往加重次数越多改善越明显。
要点
- 度普利尤单抗在2型高表达哮喘中显著减少重度急性加重54-90%。
- 既往急性加重次数越多,度普利尤单抗的疗效改善越明显。
- 无论既往加重史和基线ICS剂量,FEV1和ACQ-5均获改善。
核心结论
- 在2型生物标志物升高的中重度未控制哮喘患者中,度普利尤单抗不论既往急性加重史和基线ICS剂量均显著减少重度急性加重并改善FEV1和哮喘控制。
研究设计与样本
- LIBERTY ASTHMA QUEST(NCT02414854)3期研究的事后分析,评估度普利尤单抗200 mg和300 mg每2周 versus 安慰剂。
主要发现
- 在所有2型高表达亚组中,度普利尤单抗 versus 安慰剂显著减少重度急性加重54-90%,既往加重次数越多改善越大。
- FEV1最小二乘均值差 versus 安慰剂:≥1次加重0.15-0.25 L,≥2次加重0.12-0.32 L,≥3次加重0.09-0.38 L,多数p<0.05。
- ACQ-5最小二乘均值差:≥1次加重-0.30至-0.57,≥2次加重-0.29至-0.56,≥3次加重-0.43至-0.61,所有p<0.05。
关键数值与推荐
- 亚组按基线血嗜酸性粒细胞≥150或≥300 cells·μL-1、基线呼出气一氧化氮分数≥25 ppb和基线ICS剂量分层。
临床怎么用
- 对于2型生物标志物升高的中重度未控制哮喘患者,无论既往急性加重次数和基线ICS剂量,均可考虑使用度普利尤单抗以减少重度急性加重并改善肺功能和哮喘控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov: NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks versus placebo. This post hoc analysis assessed the effect of dupilumab on efficacy outcomes and asthma control across a range of historical exacerbation rates in patients with type 2-high asthma. METHODS: Annualised severe exacerbation rates over the 52-week treatment period, pre-bronchodilator forced expiratory volume in 1 s (FEV1) at weeks 12 and 52, and the five-item Asthma Control Questionnaire (ACQ-5) score at weeks 24 and 52 were assessed in patients with ≥1, ≥2 or ≥3 exacerbations in the previous year. Subgroups were stratified by baseline blood eosinophils ≥150 or ≥300 cells·μL-1 or baseline exhaled nitric oxide fraction ≥25 ppb and baseline inhaled corticosteroid (ICS) dose. RESULTS: Across all type 2-high subgroups, dupilumab versus placebo significantly reduced severe exacerbations by 54-90%, with greater improvements in patients with more exacerbations prior to study initiation. Similarly, improvements in FEV1 (least squares (LS) mean difference versus placebo: ≥1 exacerbations, 0.15-0.25 L; ≥2 exacerbations, 0.12-0.32 L; ≥3 exacerbations, 0.09-0.38 L; majority p<0.05) and ACQ-5 score (LS mean difference range: ≥1 exacerbations, -0.30 to -0.57; ≥2 exacerbations, -0.29 to -0.56; ≥3 exacerbations, -0.43 to -0.61; all p<0.05) were observed, irrespective of prior exacerbation history, across all subgroups. CONCLUSIONS: Dupilumab significantly reduced severe exacerbations and improved FEV1 and asthma control in patients with elevated type 2 biomarkers irrespective of exacerbation history and baseline ICS dose.
引用
- Corren J, Katelaris CH, Castro M, et al. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. Eur Respir J. 2021. PMID: 34266940. doi:10.1183/13993003.04498-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。